NL-OMON30669已完成不适用
Phase I and IIa trial for assessment of safety, immunogenicity and efficacy against sporozoite challenge of the candidate malaria vaccine PfLSA-3-rec. - LSA-3-rec
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Male and female age >=18 and <= 45 years
- •-Good general health based on history, physical en laboratory examination
- •-Available for and willingness to undergo a P. falciparum sporozoite challenge following the immunization course
- •-Resident near the Radboud University Medical Center Nijmegen, having 24h access to a telephone
- •-Living with a third party that could contact the clinicians in case of alteration of conscience
- •-Agreement to refrain from blood donation during the course of the study and afterwards
- •-Negative pregnancy test and the use of effective contraception during the whole study period
排除标准
- •-Any history of malaria
- •-Known exposure to malaria in the previous 6 months, defined as a visit to a malaria-endemic region. For practical purposes, all regions for which malaria chemoprophylaxis is advised by The Dutch National Coordination Centre for Travellers Health (LCR) are considered malaria-endemic
- •-Planned to travel to endemic malaria areas during the study period
- •-Prior administration of an investigational malaria vaccine
- •-Administration of a vaccine or gammaglobulin not foreseen by the clinical trial protocol within 30 days prior to the first immunisation and up to six months after the last immunisation.
- •-Participation in any other clinical trial within 90 days prior to the onset of the trial or more than four clinical trials in the past year
- •-The use of chronic immunosuppressive drugs or other immune modifying drugs within three months of vaccination (inhaled and topical corticosteroids are allowed)
- •-Positive serological tests for P falciparum (LSA-3) ELISA and/or a positive P. falciparum PCR
- •-Known hypersensitivity to vaccine components
- •-Contra-indications to Riamet® including treatment taken by the volunteers that interfere with Riamet® (e.g. concurrent use of medicines that prolong QT-interval)
- •- Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers
- •-An estimated, ten year risk of fatal cardiovascular disease of >=5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.
研究者
相似试验
进行中（未招募）
1 期
VAC079; a study to the assess the safety and efficacy of the malaria vaccine PvDBPII in Matrix M1EUCTR2019-002872-14-GBniversity of Oxford / Clinical Trials and Research Governance24
进行中（未招募）
1 期
A study to assess the new malaria vaccine RH5.1/AS01EUCTR2016-001718-31-GBniversity of Oxford, CTRG84
尚未招募
1 期
CIGB-Mambisa/Abdala in convalescentsCOVID-19 ConvalescenceCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000382Center for Genetic Engineering and Biotechnology (CIGB)120
进行中（未招募）
1 期
Clinical trial evaluating the safety, neutralizing capacity and the lowest effective dose for antivenom treatment of multiple Africanized bees stings Apis melliferaRBR-3fthf8Faculdade de Medicina de Botucatu
进行中（未招募）
不适用
Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of cells transduced with a therapeutic lentiviral vector for patients with Fanconi Anemia Subtype A.EUCTR2011-006100-12-ESFUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS5